Akorn Pharmaceuticals

Akorn Investor Relations

Press Releases

Date Title  
07/11/19 Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call Printer Friendly Version
06/28/19 Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% Printer Friendly Version
06/25/19 Akorn Receives FDA Warning Letter Printer Friendly Version
05/30/19 Akorn to Present at the Jefferies 2019 Global Healthcare Conference Printer Friendly Version
05/20/19 Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% Printer Friendly Version
05/20/19 Akorn to Present at the RBC Capital Markets Healthcare Conference Printer Friendly Version
05/07/19 Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance Printer Friendly Version
04/18/19 Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5% Printer Friendly Version
04/18/19 Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) Printer Friendly Version
04/15/19 Akorn to Report First Quarter 2019 Financial Results and Host Conference Call Printer Friendly Version
03/21/19 Akorn Names Erislandy (Dandy) Dorado-Boladeres as Executive Vice President of Global Quality Printer Friendly Version
03/01/19 Akorn Comments on Favorable Court Order Printer Friendly Version
02/28/19 Akorn Provides Fourth Quarter and Full Year 2018 Results Printer Friendly Version
02/20/19 Akorn Comments on Fresenius’ Proposed Amended Claims Printer Friendly Version
02/11/19 Akorn to Report Fourth Quarter and Full Year 2018 Results Printer Friendly Version
01/28/19 Akorn Announces New Executive and Board Appointments Printer Friendly Version
01/09/19 Akorn Receives FDA Warning Letter Printer Friendly Version
01/08/19 Akorn Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Printer Friendly Version